Document is current

Any future updates will be listed below

Abecma® - erste CAR-T-Zell-Therapie bei stark vorbehandelten Myelompatienten

Crossref DOI link: https://doi.org/10.1007/s15015-022-3902-3

Published Online: 2022-09-01

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark